BrUOG-E-215-Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001
32 patients with esophageal or gastroesophageal junction cancer will receive Radiation:50.4
Gy at 180cGy fraction/day for 28 treatments and Paclitaxel Poliglumex (PPX) and Cisplatin
weekly times 6 followed by surgery.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Complete pathologic response as determined at
At Surgery approximately 4weeks after last treatment
No
Howard Safran, MD
Principal Investigator
Brown University
United States: Food and Drug Administration
BrUOG-E-215
NCT00522795
August 2007
April 2010
Name | Location |
---|---|
Lifespan Hospitals | Providence, Rhode Island 02903 |